ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 836

B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation

Rochelle D. Vergroesen1, Linda Slot1, Lise Hafkenscheid1, Marvyn T. Koning2, Ellen I.H. van der Voort3, Christine A. Grooff1, George Zervakis2, Tom W.J. Huizinga1, Theo Rispens4, Hendrik Veelken2, Rene E.M. Toes1 and Hans U. Scherer3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hematology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Immunopathology, Sanquin Research, Amsterdam, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ACPA, B cell tolerance, B cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

The vast majority (>90%) of anti-citrullinated protein antibodies (ACPA) of the IgG isotype in serum and synovial fluid of patients with rheumatoid arthritis carry N-linked glycans in the antibody variable region. This remarkable degree of Fab-glycosylation is absent from ACPA-depleted control IgG and from autoantibodies in other diseases. N-glycosylation requires a specific amino acid consensus sequence in the protein backbone (termed an N-glycosylation site), which is very rare in germline-encoded variable region genes. Here, we analysed the B cell receptor (BCR) repertoire of ACPA-expressing B cells to understand the molecular basis for this remarkable glycosylation.

Methods:

We used anchoring reverse transcription of immunoglobulin (Ig) sequences and amplification by nested PCR (ARTISAN) to obtain full-length rearrangements of ACPA-expressing B cells. ACPA-expressing B cells and non citrulline-reactive control B cells were obtained from peripheral blood of patients with established RA by antigen-specific tetramer staining and fluorescence activated cell sorting. Cells were either sorted in pools, or sorted as single cells. Somatic mutations and N-glycosylation sites were identified in the sequence reads using IMGT (High)V-QUEST. Paired heavy and light chain sequences (HC/LC) were used to model the spatial positioning of N-glycosylation sites.

Results:

Sequence analysis of pools of cells identified 97 unique ACPA-IgG clones derived from n=8 donors. 87 unique ACPA-IgG clones were retrieved from single cell analysis (n=6 donors). In both datasets, over 80% of ACPA-IgG clones contained N-glycosylation sites in both HC and LC. All sites were created by somatic mutations. The mutation rate did not correlate with the number of N-glycosylation sites, and their distribution across the variable region and their preference differed from the pattern seen in controls. Structural modelling predicted N-glycosylation sites on the exterior of the antibody molecule.

Conclusion:

ACPA-expressing B cells generate BCRs with a high frequency of N-glycosylation sites. Frequency and localization of sites suggest that ACPA-expressing B cells gain a selective survival advantage by acquiring glycans in the variable domain, thereby escaping from putative checkpoints in B cell selection.


Disclosure: R. D. Vergroesen, None; L. Slot, None; L. Hafkenscheid, None; M. T. Koning, None; E. I. H. van der Voort, None; C. A. Grooff, None; G. Zervakis, None; T. W. J. Huizinga, None; T. Rispens, None; H. Veelken, None; R. E. M. Toes, None; H. U. Scherer, None.

To cite this abstract in AMA style:

Vergroesen RD, Slot L, Hafkenscheid L, Koning MT, van der Voort EIH, Grooff CA, Zervakis G, Huizinga TWJ, Rispens T, Veelken H, Toes REM, Scherer HU. B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cell-receptor-sequencing-of-anti-citrullinated-protein-antibody-expressing-b-cells-indicates-a-selective-advantage-for-the-introduction-of-n-glycosylation-sites-during-somatic-hypermutation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-receptor-sequencing-of-anti-citrullinated-protein-antibody-expressing-b-cells-indicates-a-selective-advantage-for-the-introduction-of-n-glycosylation-sites-during-somatic-hypermutation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology